RISPERDAL News
Most Popular RISPERDAL Story
ALSO NOTED: FDA rejects Risperdal for Alzheimer's; Elan CEO bullish on Tysabri's return; Myogen, Novartis expand pact; and much
> Johnson & Johnson says the FDA has turned thumb's down on Risperdal as a treatment of psychosis in Alzheimer's. Read more...
Latest Headlines
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
